Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 273

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 273
---
of the Issue

Not
applicable.

ITEM 10. ADDITIONAL
INFORMATION

A. Share Capital

Not
applicable.

B. Memorandum
and Articles of Association

A
copy of our amended and restated articles of association is attached as Exhibit 1.1 to this annual report. The information called for
by this Item is set forth in Exhibit 2(d) to this annual report and is incorporated by reference into this annual report.

C. Material
Contracts

The
following is a summary of each material contract, other than material contracts entered into in the ordinary course of business, to which
we are or have been a party, for the two years immediately preceding the date of this annual report:

  ATM Sales Agreement, dated                                                                                                    
  March 4, 2022 by and between NLS Pharmaceutics Ltd. and Virtu Americas LLC. See Item 5. “ Operating and Financial Review and  
  Prospects – Recent Financing Agreements” for more information about this document.                                            
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Short Term Loan Agreement,                                                                                                                   
  dated September 28, 2023 by and between NLS Pharmaceutics Ltd., and Ronald Hafner. See Item 5. “ Operating and Financial Review              
  and Prospects – Recent Financing Agreements” for more information about this document.                                                       
  Short Term Loan Agreements,                                                                                                                  
  dated November 15, 2023, by and between NLS Pharmaceutics Ltd., and certain existing shareholders of the Company, including Ronald           
  Hafner, the Company’s Chairman of the Board of Directors, Felix Grisard, Jürgen Bauer and Maria Nayvalt. See Item 5. “ Operating             
  and Financial Review and Prospects – Recent Financing Agreements” for more information about this document.                                  
  License Agreement, dated                                                                                                                     
  March 19, 2024, by and between NLS Pharmaceutics Ltd. and Aexon Labs, Inc., a Delaware corporation. See Item 4. “ Business Overview          
  – Additional Pre-Clinical Compounds” for more information about this document.                                                               
  Securities Purchase Agreement,                                                                                                               
  dated March 20, 2024, by and between NLS Pharmaceutics Ltd., Armistice Capital Master Fund Ltd., and Lind Global Fund II LP. See             
  Item